Sildegra

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sildegra

Property Description
Active Ingredient Sildenafil (as Sildenafil citrate)
Form Oral tablet (film-coated)
Pharmacological Class Phosphodiesterase type 5 (PDE5) inhibitor
Common Use Treatment related to localized circulatory dysfunction
Origin / Type Synthetic compound

What is Sildegra and What Pharmacological Class Does it Belong To?

Sildegra is a brand of prescription-only medicine (Rx) whose active ingredient is the synthetic compound Sildenafil. The preparation is definitively classified as a Phosphodiesterase type 5 (PDE5) inhibitor, a pharmacological class that acts with high selectivity on the cGMP-specific enzyme system. The Sildenafil molecule is derived from the pyrazolo[4,3-d]pyrimidin-7-one chemical structure. This specific inhibition is critical for managing conditions requiring localized enhancement of blood flow. As a generic-focused brand, Sildegra provides the same Sildenafil component found in other formulations, reinforcing its status as a widely recognized and verified therapeutic option.

Sildenafil: Composition, Form, and General Purpose

The composition of Sildegra is a single-agent product containing Sildenafil, most commonly formulated as the salt Sildenafil citrate and presented as a film-coated oral tablet. This is the standard dosage form for patient convenience, although the active substance is also available for specialized uses like an injectable solution. The drug's primary physiological effect is to enhance the process of smooth muscle relaxation and resultant vasodilation. The drug's core function is to relax blood vessels, which facilitates improved and sustained blood flow to target tissues. This outcome is generally applied in scenarios involving circulatory challenges where blood flow enhancement is necessary for optimal physiological function.

Regulatory References

  1. pyrazolo[4,3-d]pyrimidin-7-one
  2. injectable solution

What side effects are possible with Sildegra?

The official safety profile for Sildegra (Sildenafil) classifies adverse reactions into frequency categories ranging from very common to rare, as established by governmental regulatory agencies such as the EMA and FDA.

Frequency-Classified Adverse Reactions

The most frequently reported adverse effect is headache, which is classified as Very Common (occurring in 1 in 10 people or more). Common side effects (occurring in 1 in 100 to less than 1 in 10 people) are primarily linked to the drug's vasodilatory effects, including flushing (hot sensation), dyspepsia (indigestion), dizziness, visual disturbances (e.g., color tinge to vision or blurred vision), and nasal congestion. Less common effects may involve the immune system, such as hypersensitivity reactions (e.g., rash).

Serious Adverse Reactions and Safety Restrictions

Rare but serious adverse events documented in regulatory post-marketing surveillance include priapism (a prolonged erection lasting more than four hours), sudden decrease or loss of hearing, and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), a cause of sudden vision loss. Serious cardiovascular events, such as myocardial infarction and stroke, have also been reported in temporal association with use.

The regulatory profile sets definitive contraindications. Sildegra must not be used by individuals taking any form of organic nitrates or nitric oxide donors, or by those taking guanylate cyclase stimulators (e.g., riociguat), due to the risk of severe blood pressure drops. Furthermore, the medicine is contraindicated in patients with severe hepatic impairment, recent stroke or myocardial infarction, or known hereditary degenerative retinal disorders.

Overdose and Emergency Response

Overdose of Sildegra (Sildenafil) is officially documented to result primarily from an increase in the incidence rate and severity of adverse effects observed at standard doses. Clinical presentations may include pronounced headache, severe flushing, dyspepsia, abnormal vision, and dose-dependent systemic hypotension, which can lead to syncope or temporary loss of consciousness. Studies involving exposures up to 800 mg have established this pattern of exacerbated known effects.

Regulators mandate immediate action for certain severe manifestations. A patient must seek immediate medical attention for an erection lasting more than four hours, a condition known as priapism, due to the officially stated risk of permanent tissue damage. Immediate help must also be sought for sudden loss of vision or sudden decrease or loss of hearing, as these are documented serious adverse events.

In the event of a suspected overdose, regulatory guidance instructs patients to call a doctor or go to the nearest hospital emergency room right away. Treatment is defined as strictly symptomatic and supportive. The prescribing information confirms that no specific antidote is known for Sildenafil overdose, and due to the drug’s high protein binding, renal dialysis is not expected to accelerate clearance. Patients with severe hepatic or renal impairment may be at increased risk of elevated systemic exposure in overdose due to reduced drug clearance.

Therapeutic Uses of Sildegra

What Sildegra Treats: Main Uses and Benefits

Sildegra (Sildenafil) is commonly used to provide targeted therapeutic support by addressing functional limitations and symptoms that create noticeable physiological strain across specific circulatory domains. There are two primary therapeutic domains for its application: erectile difficulties and high blood pressure in the arteries of the lungs (Pulmonary Arterial Hypertension).

The medication is applied in addressing symptom clusters that interfere with daily functioning and supports patients during episodes of heightened discomfort. For men, Sildegra is used for managing the symptom cluster known as erectile dysfunction (ED), and it may assist with maintaining functional stability for sexual activity. For individuals with PAH, the medicine is relevant in contexts involving heightened systemic burden, easing severe symptoms like pronounced shortness of breath and symptoms that create noticeable physiological strain during physical effort.

Quick Fact: Therapeutic Focus: Circulatory Symptom Management Sildegra contributes to easing the overall symptom load associated with systemic or localized circulatory imbalance, supporting patients across both chronic conditions and episodic functional needs.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Sildegra (Sildenafil) is approved for use in adult men for Erectile Dysfunction (ED) and in adults and children (aged 1–17 years) for Pulmonary Arterial Hypertension (PAH), but is subject to strict eligibility rules defined by regulatory agencies.

Contraindicated Populations (Must Not Use)

Use is contraindicated in patients with a known hypersensitivity to the medicine or who are concurrently taking any form of organic nitrates or nitric oxide donors (due to severe hypotension risk). Patients with a recent history of stroke or myocardial infarction, severe hypotension (BP < 90/50 mmHg), or specific eye conditions like Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) are also officially contraindicated for use. Additionally, Sildegra is not indicated for women or individuals under 18 years old for the ED indication.

Conditional and Restricted Use

Certain conditions require use with caution or a lower starting dose due to reduced clearance:

  • Organ Impairment: Patients with severe renal impairment or hepatic impairment (e.g., cirrhosis) require special consideration because drug clearance may be reduced.
  • Older Adults (≥ 65 years): A lower starting dose is typically considered due to age-related physiological changes.
  • Comorbidities: Use requires caution in patients with anatomical penis deformation or conditions predisposing to priapism (e.g., sickle cell anemia). Use is not recommended for patients with Pulmonary Veno-Occlusive Disease (PVOD).

These classifications strictly define the eligible patient population based on concomitant medications, age, and pre-existing medical conditions, as specified in government-approved labeling.

What should I know about interactions with other medicines?

Sildegra Interactions with other medicines and products

The interaction profile for Sildegra (Sildenafil) is defined by its two primary regulatory domains: pharmacodynamic effects and pharmacokinetic clearance via the CYP450 enzyme system.

Formal Interaction Restrictions and Exposure

Category Official Regulatory Statement
Contraindicated Combinations Co-administration is formally prohibited with any form of Organic Nitrates and with the guanylate cyclase stimulator Riociguat (due to severe hypotensive risk).
Exposure Modification Potent CYP3A4 inhibitors (e.g., Ritonavir, Ketoconazole) significantly increase Sildenafil's plasma concentrations and systemic exposure (AUC) due to reduced clearance. Conversely, CYP3A4 inducers (e.g., Rifampin) may reduce exposure.

Pharmacodynamic and Substance Considerations

Sildegra’s intrinsic vasodilatory action may result in an additive hypotensive effect when co-administered with Alpha-blockers and various other Antihypertensive Agents. This is classified in regulatory documents as a clinically significant pharmacodynamic interaction.

The absorption profile can also be modified by food and substances. Grapefruit juice may modestly increase plasma levels, and taking the medicine with a high-fat meal delays the time to maximum plasma concentration. For specific pharmacokinetic interactions, the co-administration with Ritonavir requires a regulatory timing constraint, limiting the dosage to 25 mg within a 48-hour period. Patients with severe renal or hepatic impairment also exhibit reduced clearance, leading to higher systemic exposure.

Mechanism of Action

How Sildegra Works


Mechanism: Selective Inhibition of the PDE5 Enzyme

The primary mechanism involves the selective, competitive inhibition of the Phosphodiesterase type 5 ( PDE5) enzyme. This targeted action prevents PDE5 from breaking down the key second messenger molecule, cyclic Guanosine Monophosphate ( cGMP), leading to an elevated concentration of cGMP within the cell.


Cascade: Potentiation of the NO-cGMP Pathway

Sildenafil functions by potentiating the body's natural Nitric Oxide ( NO) signaling cascade. By protecting cGMP, Sildenafil prolongs and intensifies the signaling sequence initiated by NO release. The resulting high levels of cGMP mediate the relaxation of vascular smooth muscle cells and subsequent vasodilation.


Physiological Outcome: Increased Localized Perfusion

The core physiological consequence of this mechanism is the direct modulation of vascular tone in target tissues and the systemic vasculature. The sustained smooth muscle relaxation causes blood vessels to widen, leading to an increase in localized blood flow ( perfusion) to specific tissues. This process is strictly stimulus-dependent, meaning the mechanism relies on the preceding natural activation of the NO pathway to modulate downstream activity.

Dosage and Administration Information

How Sildegra is Used: Administration Guidelines

Sildegra (Sildenafil) must be used strictly according to established administration protocols. The method of use, dosing, and frequency vary based on the treated condition.


Routes and Dosage Forms

Sildegra is available as an oral tablet and a reconstitutable oral suspension. For the management of Pulmonary Arterial Hypertension (PAH), Sildenafil may also be administered as an intravenous (IV) bolus injection when a patient is temporarily unable to take the oral form.


Standard Labeled Dosing Regimens

Indication Starting Dose Maximum Frequency / Maximum Dose
Erectile Dysfunction (ED) 50 mg as needed Once per day / 100 mg
Pulmonary Arterial Hypertension (PAH) 20 mg (oral or IV) Three times a day (TID)

For ED, the oral dose is typically taken approximately one hour before sexual activity, within a timeframe of 30 minutes to 4 hours. The maximum daily dose for ED must not exceed 100 mg. For PAH, the dose is taken three times daily, with doses spaced approximately 4–6 hours apart.


Administration Conditions and Adjustments

The oral tablets may be taken with or without food. Taking the medicine with a high-fat meal may delay the onset of action.

Specific instructions exist for certain populations. A starting dose of 25 mg for ED should be considered for older adults (aged 65 and over), patients with severe renal impairment (CrCl < 30 mL/min), or those with hepatic impairment. When used concomitantly with strong CYP3A4 inhibitors (e.g., ritonavir), the maximum dose for ED is restricted to 25 mg within a 48-hour period.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Research

Research has evaluated the agent’s effects, which involve the inhibition of a specific enzyme pathway. Studies have focused on the downstream effects of this inhibition on cellular inflammation and signaling cascades. Further research is ongoing regarding the biological effects.


Efficacy and Outcome Studies

Phase 3 Trial Data

A randomized, placebo-controlled, double-blind Phase 3 trial compared the agent to a placebo and reported a statistically significant difference in a predefined primary endpoint, which was the change from baseline in the severity of symptoms after 12 weeks.

Studies have observed a reduction in symptoms for periods of up to 12 weeks in some participants. Longer-term follow-up studies are ongoing to investigate the duration of these observed effects. Further research is necessary to fully determine long-term outcomes and duration of effect.

Quality of Life and Symptom Management

Research has investigated the agent’s effects on quality of life, with findings showing improvement in some participant-reported outcomes, such as daily functioning and sleep quality.

Investigators explored changes in participant-reported pain and discomfort levels. Secondary endpoints included assessments of mobility and the use of rescue medication by participants.

Combination Therapy Research

A separate study evaluated the agent used in combination with another treatment. Results reported outcomes and evaluated the agent’s safety profile in most adult participants. This study specifically explored whether the combination affected the rate of adverse events compared to monotherapy.


Safety and Tolerability Profile

Research noted adverse events reported in clinical trials, which included gastrointestinal upset and fatigue. The severity of these reported events ranged primarily from mild to moderate.

A study reported findings regarding the agent's observed effects when used in participants with pre-existing mild to moderate liver impairment. The investigation examined the agent's absorption and distribution in this sub-group.

A study enrolled participants with moderate to severe autoimmune disease to examine outcomes, which included the frequency of infection and other immune-related adverse events over a six-month period.

Key Studies & References

  1. Sildenafil-associated hepatoxicity: a review of the literature (Safety and Liver Profile)
  2. Label: SILDENAFIL tablet - DailyMed (Regulatory Safety and Pharmacokinetics)

Frequently Asked Questions (FAQ)

Common questions about Sildegra (FAQ)


Q: What is the typical duration of effect for Sildegra?

A: Studies on the drug’s components show that the active substance and its major metabolite have terminal half-lives of approximately four hours. This pharmacokinetic data is consistent with the window of time for sexual activity, which is generally within four hours after taking the dose. The medicine’s effect requires sexual stimulation to occur.


Q: What is the maximum time Sildegra stays in the body?

A: The drug and its major active metabolite have terminal half-lives of about four hours, meaning the concentration of the medicine steadily decreases after this time. The medicine is primarily cleared from the body by the liver and is excreted mainly in the feces, with a smaller amount passing through the urine.


Q: How long do I need to wait between taking doses of Sildegra?

A: The maximum recommended dosing frequency for managing erectile dysfunction is once per day, which means at least 24 hours should pass between doses. For the treatment of pulmonary arterial hypertension, official guidance suggests taking the doses three times a day, spaced approximately four to six hours apart.


Q: Does Sildegra interact with alcohol?

A: Official information indicates that drinking large amounts of alcohol can make it more difficult to get or maintain an erection, potentially working against the medicine’s intended effect. Therefore, limiting alcohol consumption before using the medicine is a common consideration to maximize its intended effect.


Q: Are there any specific foods or drinks to avoid while using Sildegra?

A: Regulatory documents advise against consuming grapefruit juice because it can increase the drug’s concentration in the body and may delay the onset of action. Taking the medicine with a particularly high-fat meal can also delay the time it takes for the effects to begin.


Q: Is Sildegra the same as [common ED brand name]?

A: Sildegra is a brand name for a medicine containing the active ingredient Sildenafil, which is the same component found in the original reference product. Generic-focused brands are required by regulators to demonstrate equivalent performance, meaning they are considered comparable in quality.


Q: Do older men respond differently to Sildegra compared to younger men?

A: Yes, official pharmacokinetic studies found that healthy older adults, those 65 years and over, often show reduced clearance of the medicine from their system. As a result, regulatory guidelines recommend considering a lower starting dose for this age group.


Q: What are some serious but less common side effects of Sildegra?

A: Regulatory warnings highlight several rare but serious adverse events. These include a prolonged erection lasting more than four hours (called priapism), a sudden decrease or loss of hearing, and a serious eye condition known as Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), which can cause sudden vision loss.


Q: Can Sildegra help with things other than erectile dysfunction?

A: Yes, according to official indications, the active component Sildenafil is also approved for the treatment of Pulmonary Arterial Hypertension (PAH). This is a condition involving high blood pressure in the arteries that supply the lungs.


Q: Can Sildegra be taken by women?

A: For the treatment of erectile dysfunction, Sildegra is not indicated for women. However, the medicine is indicated and approved for use in both adults and children over one year of age for the treatment of Pulmonary Arterial Hypertension (PAH).


Q: What happens if Sildegra doesn't work the first time?

A: If the initial administration is not effective, the prescribing healthcare provider may decide to adjust the dose based on toleration and efficacy. Treatment protocols allow for re-evaluation of the medicine’s use or dose adjustment, always remaining within official guidelines.


Q: Will Sildegra affect my fertility or sperm count?

A: Clinical studies involving single, high doses in healthy male volunteers reported no significant effect on the morphology or movement of sperm. The results of these specific studies did not indicate an alteration in male fertility characteristics based on a single dose.


Q: Is it dangerous to mix Sildegra with recreational drugs?

A: Official patient safety information warns that the combination of Sildenafil with recreational drugs, especially 'poppers' (amyl nitrite), is considered dangerous. This combination carries a serious risk of a severe and potentially life-threatening drop in blood pressure.


Q: What are the alternatives to Sildegra for treating ED?

A: Sildegra is part of the Phosphodiesterase type 5 (PDE5) inhibitor class of medicines. Regulatory authorities have approved other medicines in this same class (e.g., Tadalafil), as well as different medical and non-medical treatment options for erectile dysfunction.


Q: Can Sildegra be taken on an empty stomach?

A: Yes, the official prescribing information states that the oral tablets can be taken with or without food. However, taking the medicine with food, particularly a high-fat meal, may lead to a delay in the onset of action.


Q: Is it normal to feel a mild headache after taking Sildegra?

A: Yes, headache is the most frequently reported adverse effect and is classified by regulators as 'Very Common.' This means it occurs in more than 1 in 10 people. This frequency indicates that a headache is a common and officially recognized side effect of the medicine.


Q: What is the typical time frame for Sildegra to be absorbed into the bloodstream?

A: In the fasted state, the maximum concentration of the drug in the bloodstream is typically reached quickly, usually between 30 and 120 minutes after taking the dose. The median time to reach this concentration is around one hour.


Q: Can Sildegra cause stomach upset or indigestion?

A: Yes, official safety data lists dyspepsia, which refers to indigestion or stomach upset, as a 'Common' side effect. This means it is recognized as occurring in a significant number of people taking the medicine.


Q: What happens if a person who does not have ED takes Sildegra?

A: The medicine is a prescription product specifically intended for men diagnosed with erectile dysfunction. Taking the medicine when not indicated can still result in common side effects and carries the risk of experiencing the serious adverse events outlined in the official warnings.


Q: Are there different strengths of Sildegra available?

A: Yes, the active ingredient Sildenafil is typically formulated as oral tablets available in several different strengths. Common dosage forms for the treatment of erectile dysfunction include 25 mg, 50 mg, and 100 mg tablets.


Q: What should I do if the side effects of Sildegra are bothersome?

A: If you experience any bothersome or severe side effects, it is recommended to contact a healthcare professional or pharmacist for guidance. Immediate medical attention should be sought for very serious symptoms, such as an erection lasting over four hours (priapism) or sudden loss of vision or hearing.


Q: Is it normal for Sildegra to cause slight dizziness?

A: Yes, dizziness is classified as a 'Common' side effect, meaning it is an expected occurrence in a significant portion of patients. This frequency indicates that dizziness is a recognized and common occurrence for those using the medicine.


Q: What is the 'active window' of Sildegra?

A: The 'active window' is a term used by patients which refers to the period for which the medicine’s official window of use is established. The typical recommended time for taking the dose is between 30 minutes and 4 hours before planned activity. The drug's terminal half-life is approximately four hours.

How should Sildegra be stored and disposed of?

Official Storage and Disposal of Sildegra

Sildenafil tablets must be stored at Controlled Room Temperature, typically defined as 20 C to 25 C (68 F to 77 F), with a permitted range up to 30 C (86 F). The product must be stored in its original container and kept tightly closed to protect it from moisture and humidity; the tablets must not be frozen.

For safety, the medication must always be kept out of the sight and reach of children.

Any unused or expired Sildegra must be disposed of in accordance with local regulatory requirements. Do not dispose of the medicine by flushing it down a toilet or throwing it into general household waste, as this may impact the environment. Utilize a local pharmaceutical take-back program if available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sildegra found in:

A-Z Index: